The Swedish Companies Registration Office has approved and registered the company’s change of name from Pharmalink AB to Calliditas Therapeutics AB.
STOCKHOLM, November 15, 2017: The specialty pharmaceutical company Pharmalink AB today announced that it has changed its name to Calliditas Therapeutics AB (“Calliditas Therapeutics” or the “Company”).
The Swedish Companies Registration Office has approved and registered the company’s change of name from Pharmalink AB to Calliditas Therapeutics AB. More information about Calliditas Therapeutics and its clinical projects can be found on the new website www.calliditas.se.
For further information, please contact:
Calliditas Therapeutics AB
Renée Aguiar-Lucander, Chief Executive Officer
Mobile: +46 (0)72 252 1006
Email: renee.lucander@calliditas.se
Mikael Widell, Head of Communications
Mobile: +46 (0)70 311 9960
Email: mikael.widell@calliditas.se
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
Email: calliditas@optimumcomms.com
Tel: +44 (0) 203 714 1787
